Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA.

Oncogene. 2005 Oct 20;24(46):6861-9.

PMID:
16007148
2.

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH.

J Biol Chem. 2007 Oct 12;282(41):29831-46. Epub 2007 Aug 13.

3.

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.

Rahmani M, Davis EM, Bauer C, Dent P, Grant S.

J Biol Chem. 2005 Oct 21;280(42):35217-27. Epub 2005 Aug 18.

4.
5.

Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).

Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D.

Mol Med. 2012 Feb 10;18:19-28. doi: 10.2119/molmed.2011.00164.

6.
7.
8.

Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.

Huang S, Sinicrope FA.

Mol Cancer Ther. 2010 Mar;9(3):742-50. doi: 10.1158/1535-7163.MCT-09-1004. Epub 2010 Mar 2.

9.

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P.

Clin Cancer Res. 2007 Aug 15;13(16):4934-42. Epub 2007 Jul 25.

11.

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, Bottos A, Gammaitoni L, Migliardi G, Camussi G, Alberghini M, Torchio B, Ferrari S, Bussolino F, Fagioli F, Picci P, Aglietta M.

Mol Cancer. 2009 Dec 10;8:118. doi: 10.1186/1476-4598-8-118.

12.

Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.

Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC.

Cancer Res. 2008 Aug 1;68(15):6109-17. doi: 10.1158/0008-5472.CAN-08-0579.

13.

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS.

Cancer Cell. 2007 Jul;12(1):66-80.

14.

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y.

Oncogene. 2007 Jun 7;26(27):3972-9. Epub 2006 Dec 18.

PMID:
17173063
15.

The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.

Huang R, Chen XQ, Huang Y, Chen N, Zeng H.

Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.

16.

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.

Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA.

Mol Cancer Ther. 2006 Sep;5(9):2378-87.

17.

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.

Panka DJ, Wang W, Atkins MB, Mier JW.

Cancer Res. 2006 Feb 1;66(3):1611-9.

18.

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.

Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F.

J Invest Dermatol. 2011 Feb;131(2):468-79. doi: 10.1038/jid.2010.297. Epub 2010 Oct 14.

19.

Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis.

Han J, Goldstein LA, Gastman BR, Rabinowich H.

J Biol Chem. 2006 Apr 14;281(15):10153-63. Epub 2006 Feb 13.

20.

Supplemental Content

Support Center